Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers

MLA

Schmitt-Hoffmann, Anne, et al. “Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers.” Antimicrobial Agents and Chemotherapy, vol. 50, no. 1, Jan. 2006, pp. 279–85. EBSCOhost, https://doi.org/10.1128/AAC.50.1.279-285.2006.

APA

Schmitt-Hoffmann, A., Roos, B., Heep, M., Schleimer, M., Weidekamm, E., Brown, T., Roehrle, M., & Beglinger, C. (2006). Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 50(1), 279–285. https://doi.org/10.1128/AAC.50.1.279-285.2006

Chicago

Schmitt-Hoffmann, Anne, Brigitte Roos, Markus Heep, Michael Schleimer, Erhard Weidekamm, Tom Brown, Michael Roehrle, and Christoph Beglinger. 2006. “Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers.” Antimicrobial Agents and Chemotherapy 50 (1): 279–85. doi:10.1128/AAC.50.1.279-285.2006.